Emergent BioSolutions has sold its travel health business to Bavarian Nordic
Client: Emergent BioSolutions
Client Location: United States
Target: Travel health business of Emergent BioSolutions
Target Location: United States
Acquirer: Bavarian Nordic
Acquirer Location: Denmark
Client Description: Emergent BioSolutions (“Emergent”) provides solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that are developed and manufactured for governments and consumers. Emergent also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers worldwide.
Acquirer Description: Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. Bavarian Nordic is a global leader in smallpox and mpox vaccines, which have been developed through its long-standing partnership with the U.S. Government to enhance the public health preparedness through a strong portfolio of vaccines for travelers and endemic diseases.
Meet our Senior Team
I enhance my clients’ decision making and governance processes by providing independent and objective financial advice in a highly responsive manner.
Chris Gregory
Managing Director & Co-head of Transaction Opinions
New York
View More Transactions
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.